Wegovy vs Ozempic: same drug, different labels
Both contain semaglutide. The labels differ in what each is approved for, how the dose steps up, how high it goes and what to do after a missed dose.
Wegovy and Ozempic contain the same active ingredient, semaglutide, and both are made by Novo Nordisk [2][1]. They are separate products with separate labels. Ozempic is approved to improve blood sugar control in adults with type 2 diabetes and to lower cardiovascular and kidney risks in that group [1]. Wegovy is approved for weight reduction and long-term maintenance, to reduce cardiovascular risk in adults with established heart disease and obesity or overweight, and for a form of liver disease called MASH [2]. Ozempic’s dose steps end at 2 mg weekly, and Wegovy injection is usually maintained at 2.4 mg [1][2]. The Wegovy label says using it with other semaglutide products is not recommended [2].
Wegovy and Ozempic side by side
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide [1] | Semaglutide [2] |
| Approved uses (US label) | Improve blood sugar control in adults with type 2 diabetes. Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1] | Injection: reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Reduce excess body weight and maintain weight reduction in adults and in children 12 and older with obesity, and in adults with overweight and a weight-related condition. Treat noncirrhotic MASH with moderate to advanced fibrosis (accelerated approval). Tablets: cardiovascular risk reduction and weight reduction in adults [2] |
| Starting dose | 0.25 mg once weekly, then 0.5 mg after 4 weeks [1] | 0.25 mg once weekly, then steps every 4 weeks [2] |
| Highest dose on the label | 2 mg once weekly, only if more blood sugar control is needed after at least 4 weeks on 1 mg [1] | Injection maintenance is usually 2.4 mg once weekly, and a 7.2 mg strength is listed [2] |
| Missed dose | Give it within 5 days of the missed dose [1] | If the next dose is more than 2 days away, give it as soon as possible. If it is less than 2 days away, skip it. After 2 or more missed doses in a row, restart the dose steps at a lower dose [2] |
| Forms | Weekly pens and single-dose prefilled syringes [1] | Weekly injection (pens and syringes) and daily tablets [2] |
Why one medicine has two names
Each brand was tested and approved for its own use, at its own doses, so each has its own label. Ozempic’s label is built around type 2 diabetes. Wegovy’s is built around weight and cardiovascular risk. The molecule is the same, so the two share warnings. Both labels carry a boxed warning about thyroid C-cell tumors [1][2].
Because the labels are separate, so are the dose steps. Ozempic stops at 0.25, 0.5, 1 and 2 mg [1]. Wegovy injection steps through 0.25, 0.5, 1 and 1.7 mg to a maintenance dose, usually 2.4 mg [2]. A dose of one is not a like-for-like swap for a dose of the other. Only your prescriber can say how to move between them, and the Wegovy label’s switching section covers moving between Wegovy injection and Wegovy tablets, not Ozempic [2].
Side effects in each label’s trials
| Reported in trials | Ozempic 1 mg | Placebo (Ozempic trials) | Wegovy 2.4 mg | Placebo (Wegovy trials) |
|---|---|---|---|---|
| Nausea | 20.3% [1] | 6.1% [1] | 44% [2] | 16% [2] |
| Vomiting | 9.2% [1] | 2.3% [1] | 24% [2] | 6% [2] |
| Diarrhea | 8.8% [1] | 1.9% [1] | 30% [2] | 16% [2] |
| Constipation | 3.1% [1] | 1.5% [1] | 24% [2] | 11% [2] |
| Abdominal pain | 5.7% [1] | 4.6% [1] | 20% [2] | 10% [2] |
What the table does show is the pattern: in each trial, stomach and bowel effects were more common on the medicine than on placebo, and the labels advise stepping the dose up gradually to reduce them [1][2]. For the full side effect picture, see the GLP-1 side effects guide.
Is Ozempic approved for weight loss?
No. The Ozempic label’s approved uses are blood sugar control in type 2 diabetes and the cardiovascular and kidney uses in that group. Weight reduction is not among them [1]. Wegovy is the semaglutide label with a weight reduction indication [2]. A prescriber can choose to prescribe a medicine for a use that is not on its label, and that is a decision between you and them. This page only reports what the labels say.
Can you use both?
The Wegovy label says that using it together with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended [2]. Ozempic and Wegovy are both semaglutide, so taking both would double up on the same ingredient. If you have been prescribed one and are unsure about the other, ask your prescriber before you inject anything.
Keep a log of your own
Frequently asked questions
Is Wegovy the same as Ozempic?
They contain the same active ingredient, semaglutide, and are both made by Novo Nordisk, but they are separate products with separate labels, uses and dose steps.
Is semaglutide the same as Ozempic?
Ozempic is a brand of semaglutide. Wegovy is another. The active ingredient is the same, and the labels differ.
What is the difference between Ozempic and Wegovy?
Ozempic is approved for type 2 diabetes and related cardiovascular and kidney risk. Wegovy is approved for weight reduction, cardiovascular risk reduction in adults with heart disease and obesity or overweight, and MASH. Their dose steps, highest doses and missed dose rules differ.
Which is stronger, Wegovy or Ozempic?
The labels list different dose ranges: Ozempic’s steps end at 2 mg weekly, while Wegovy injection is usually maintained at 2.4 mg. They are approved for different uses, and only your prescriber can set your dose.
Can I take Ozempic and Wegovy together?
The Wegovy label says using it with other semaglutide-containing products is not recommended. Ask your prescriber before using both.
Do Ozempic and Wegovy have the same side effects?
Both labels list stomach and bowel effects as the most common, and both carry a boxed warning about thyroid C-cell tumors. The percentages come from different trials, so they are not a head-to-head comparison.
Sources
- OZEMPIC (semaglutide) injection: full prescribing information. Novo Nordisk, revised 05/2026. Sections 2.1 and 2.2 (administration, missed dose, dosage) and 3 (strengths).
- WEGOVY (semaglutide) injection and tablets: full prescribing information. Novo Nordisk, revised 06/2026. Sections 2.1 to 2.5 (administration, dosage, missed doses, switching) and 3 (strengths).
How we write these. Every dose, interval and window above comes from the manufacturer’s US prescribing information, checked on 6 October 2026, and links to it. Labels are updated, so check the current label or ask your pharmacist before you act. Nerra is made by Hicham Zaidi. We do not sell any medicine and are not affiliated with any manufacturer. If you spot an error, tell us through the Nerra support page.
Keep reading
Your therapy, completely in view.
Nerra is a private GLP-1 companion for Android, with iPhone coming soon: doses you enter, injection sites, weight and check-ins. No account, no cloud, pay once.
On Android now, iPhone soonNerra is not a medical device and does not provide medical advice. You always enter the dose your prescriber gave you; Nerra never calculates or suggests one. Always follow your prescriber’s instructions. Nerra is not affiliated with any medication manufacturer. Product names belong to their owners.